Literature DB >> 33393070

Paraneoplastic syndrome or immune-related adverse event? A case of rhomboencephalitis in a patient treated with Pembrolizumab.

G Abbadessa1, G Miele2, M Fratta2, S Bonavita2.   

Abstract

Entities:  

Keywords:  Case report; Immunotherapy; Neuroimmunology; Paraneoplastic neurological syndrome

Mesh：

Substances：

Year:  2021        PMID： 33393070     DOI： 10.1007/s13760-020-01564-3

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN： 0300-9009            Impact factor:   2.396


× No keyword cloud information.
  5 in total

1.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.

Authors:  Tanya J Williams; David R Benavides; Kelly-Ann Patrice; Josep O Dalmau; Alexandre Leon Ribeiro de Ávila; Dung T Le; Evan J Lipson; John C Probasco; Ellen M Mowry
Journal:  JAMA Neurol       Date:  2016-08-01       Impact factor: 18.302

2.  Amphiphysin autoimmunity: paraneoplastic accompaniments.

Authors:  Sean J Pittock; Claudia F Lucchinetti; Joseph E Parisi; Eduardo E Benarroch; Bahram Mokri; Christina L Stephan; Kwang-Kuk Kim; Manfred W Kilimann; Vanda A Lennon
Journal:  Ann Neurol       Date:  2005-07       Impact factor: 10.422

3.  Non-stiff anti-amphiphysin syndrome: clinical manifestations and outcome after immunotherapy.

Authors:  Jangsup Moon; Soon-Tae Lee; Jung-Won Shin; Jung-Ick Byun; Jung-Ah Lim; Yong-Won Shin; Tae-Joon Kim; Keon-Joo Lee; Kyung-Il Park; Keun-Hwa Jung; Ki-Young Jung; Sang Kun Lee; Kon Chu
Journal:  J Neuroimmunol       Date:  2014-07-23       Impact factor: 3.478

Review 4.  Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.

Authors:  Lidia M Yshii; Reinhard Hohlfeld; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2017-11-06       Impact factor: 42.937

5.  The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer.

Authors:  P De Camilli; A Thomas; R Cofiell; F Folli; B Lichte; G Piccolo; H M Meinck; M Austoni; G Fassetta; G Bottazzo; D Bates; N Cartlidge; M Solimena; M W Kilimann
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.